AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19069579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 19069579 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 608
Study 16152682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous mononuclear bone marrow cells (mBMC) 5-8 days after PCI
Number of subjects: 100
Study 16152682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 15117578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 2 seconds
Number of subjects: 13
Study 15117578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 4 seconds
Number of subjects: 13
Study 15117578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 2 seconds
Number of subjects: 13
Study 15117578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 4 seconds
Number of subjects: 13
Study 15117578 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of regular insulin (0.15 U/kg)
Number of subjects: 13
Study 11054617 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14500
Study 11054617 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14500
Study 11054617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 14500
Study 9172021 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 cm2 active patch delivering 50 micrograms/hr of fentanyl and a 30 cm2 placebo patch
Number of subjects: 62
Study 9172021 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 cm2 active patch delivering 75 micrograms/hr of fentanyl and a 20 cm2 placebo patch
Number of subjects: 62
Study 9172021 — intervention group
Group type: COMPARATOR
Intervention: IV PCA with morphine
Number of subjects: 62
Study 9172021 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 62
Study 9172021 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 62
Study 8268649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 36
Study 8268649 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD patients
Number of subjects: 36
Study 8268649 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 8268649 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 8268649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis and CAPD patients
Number of subjects: 36
Study 3709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 10
Study 3709629 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10
Study 3709629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3221377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt restriction (10 g to 2 g salt/day for five days)
Number of subjects: 25
Study 3221377 — intervention group
Group type: COMPARATOR
Intervention: Salt repletion (2 g salt/day to 20 g/day for five days)
Number of subjects: 25
Study 3221377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt restriction
Number of subjects: 25
Study 3221377 — intervention group
Group type: COMPARATOR
Intervention: Salt repletion
Number of subjects: 25
Study 3221377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt restriction and salt repletion
Number of subjects: 25
Study 31784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine and pirfenidone (Group 2)
Number of subjects: 22
Study 31784348 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus azathioprine (Group 1)
Number of subjects: 22
Study 31385402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar attachments
Number of subjects: 40
Study 31385402 — intervention group
Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 40
Study 28708219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Cyclosporine A cationic emulsion (CsA CE)
Number of subjects: 177
Study 28708219 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 177
Study 25728831 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK239512
Number of subjects: 50
Study 25728831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23439604 — intervention group
Group type: EXPERIMENTAL
Intervention: darapladib 40 mg
Number of subjects: 107
Study 23439604 — intervention group
Group type: EXPERIMENTAL
Intervention: darapladib 80 mg
Number of subjects: 107
Study 23439604 — intervention group
Group type: EXPERIMENTAL
Intervention: darapladib 160 mg
Number of subjects: 107
Study 23439604 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 21062330 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea along with zinc, selenium, and vitamin C (EP+)
Number of subjects: 108
Study 21062330 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (EP)
Number of subjects: 108
Study 21062330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 19320576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSF drainage)
Number of subjects: 22
Study 19320576 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 22
Study 16995871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil alone (treatment A)
Number of subjects: 16
Study 16995871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil co-administered with iron (treatment B)
Number of subjects: 16
Study 16995871 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatments A and B
Number of subjects: 16
Study 12204930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free drink
Number of subjects: 5
Study 12204930 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 5
Study 10417497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 80 mg, 120 mg, 180 mg
Number of subjects: 24
Study 10417497 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 24
Study 10417497 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 30 mg
Number of subjects: 24
Study 10417497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7590484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg)
Number of subjects: 31
Study 7590484 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (60 mg)
Number of subjects: 31
Study 7590484 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 2175149 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10
Study 2175149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 10
Study 2175149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Indomethacin and Lisinopril
Number of subjects: 10
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 16
Study 6104840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31984668 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss + Maintenance arm (16 + 12 sessions)
Number of subjects: 440
Study 31984668 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss Only arm (16 sessions)
Number of subjects: 440
Study 29444721 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G) delivered by lay community health workers (LCHWs), 12 sessions
Number of subjects: 142
Study 29444721 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of caregivers who received IPT-G
Number of subjects: 142
Study 29444721 — intervention group
Group type: COMPARATOR
Intervention: Caregivers receiving treatment as usual (TAU)
Number of subjects: 142
Study 29444721 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers receiving IPT-G
Number of subjects: 142
Study 27217448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519
Study 27217448 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study 25648055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training (N = 37)
Number of subjects: 109
Study 25648055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (N = 36)
Number of subjects: 109
Study 25648055 — intervention group
Group type: COMPARATOR
Intervention: Social group (N = 36)
Number of subjects: 109
Study 23823344 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% chlorine dioxide (ClO2) mouthrinse
Number of subjects: 11
Study 23823344 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate (CHX)
Number of subjects: 11
Study 23823344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 23823344 — intervention group
Group type: COMPARATOR
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 11
Study 23823344 — intervention group
Group type: COMPARATOR
Intervention: 0.05% CPC
Number of subjects: 11
Study 22043076 — intervention group
Group type: EXPERIMENTAL
Intervention: Pour-on ivermectin
Number of subjects: 0
Study 22043076 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable ivermectin
Number of subjects: 0
Study 22043076 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 0
Study 18504096 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients (AA)
Number of subjects: 898
Study 18504096 — intervention group
Group type: COMPARATOR
Intervention: European American patients (EA)
Number of subjects: 898
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of portal hypertensive gastropathy (PHG)
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal mosaic pattern
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Red marks
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric antral vascular ectasia (GAVE) features
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent correlates of PHG
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent correlates of GAVE
Number of subjects: 1016
Study 16573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between PHG and esophageal varices
Number of subjects: 1016
Study 12759758 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive incremental lifting and lowering (RILL) at 10 lifts/min to voluntary fatigue
Number of subjects: 32
Study 12759758 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive incremental lifting and lowering (RILL)
Number of subjects: 32
Study 12759758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory, hemodynamic and body composition variables
Number of subjects: 32
Study 12759758 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of left side OXY/BV responses
Number of subjects: 32
Study 10947577 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for a one month reduction in waiting time for cataract surgery.
Number of subjects: 0
Study 10947577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost consumer surplus due to cataract surgery queue.
Number of subjects: 0
Study 8853469 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI)
Number of subjects: 8
Study 8853469 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 2054270 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa combination (Sinemet Plus)
Number of subjects: 14
Study 2054270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6357631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg Sulprostone gel
Number of subjects: 30
Study 6357631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg PGE2 gel
Number of subjects: 30
Study 6357631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05mg Sulprostone gel
Number of subjects: 30
Study 31770060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, and dexamethasone (VRD) followed by autologous transplantation and two consolidation courses with VRD
Number of subjects: 458
Study 31770060 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance (lenalidomide and ixazomib)
Number of subjects: 458
Study 31770060 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable MRD
Number of subjects: 458
Study 31770060 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised International Staging System III status and positive MRD
Number of subjects: 458
Study 30411328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening participation
Number of subjects: 0
Study 30411328 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in mammography screening
Number of subjects: 0
Study 30316999 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanCope program (pain self-management skills training including personalized CBT-based coping skills such as deep breathing, relaxation, and cognitive skills)
Number of subjects: 160
Study 30316999 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (self-guided website with education about SCD)
Number of subjects: 160
Study 30316999 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanCope program
Number of subjects: 160
Study 27894295 — intervention group
Group type: EXPERIMENTAL
Intervention: WebCONSORT
Number of subjects: 324
Study 27894295 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 324
Study 24571619 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration using the Eliminate aspiration catheter (Terumo Medical Supply, Japan)
Number of subjects: 128
Study 24571619 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary percutaneous coronary intervention (PCI)
Number of subjects: 128
Study 24571619 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 128
Study 24571619 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 128
Study 22512481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (fluorouracil 500 mg/m²/day during fractions 1 to 5 and 16 to 20 of radiotherapy, mitomycin C 12 mg/m² on day 1)
Number of subjects: 360
Study 22512481 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 360
Study 22512481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 360
Study 20079760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (n=54): Supporters received monthly contacts from a counselor about providing effective support.
Number of subjects: 82
Study 20079760 — intervention group
Group type: COMPARATOR
Intervention: Control (n=28): Supporters were not contacted.
Number of subjects: 82
Study 20079760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (n=54) at end of pregnancy
Number of subjects: 82
Study 20079760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (n=54) at 3 months postpartum
Number of subjects: 82
Study 18164334 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 29
Study 18164334 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 29
Study 16149980 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention group (n=60)
Number of subjects: 180
Study 16149980 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=60)
Number of subjects: 180
Study 16149980 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=60)
Number of subjects: 180
Study 13130460 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIT program (2-year intensive exercise program)
Number of subjects: 309
Study 13130460 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 309
Study 10382786 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra at a dose of 1 mg/kg/h (n = 20)
Number of subjects: 71
Study 10382786 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra at a dose of 2 mg/kg/h (n = 22)
Number of subjects: 71
Study 10382786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 71
Study 8808137 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine
Number of subjects: 6
Study 8808137 — intervention group
Group type: EXPERIMENTAL
Intervention: IV saline
Number of subjects: 6
Study 8808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 6
Study 8808137 — intervention group
Group type: COMPARATOR
Intervention: Standard 1-mg cigarette
Number of subjects: 6
Study 1418276 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms.kg‐1)
Number of subjects: 100
Study 1418276 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (5 micrograms.kg‐1)
Number of subjects: 100
Study 6326178 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 54
Study 6326178 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 54
Study 6326178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 30148994 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGWT)
Number of subjects: 100
Study 30148994 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided cannulation over a pancreatic stent (WGC-PS)
Number of subjects: 100
Study 29385990 — intervention group
Group type: EXPERIMENTAL
Intervention: Urox® (Crataeva nurvala stem bark, Equisetum arvense stem, Lindera aggregata root)
Number of subjects: 150
Study 29385990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27426680 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach for vaginal cuff closure
Number of subjects: 70
Study 27426680 — intervention group
Group type: COMPARATOR
Intervention: Vaginal route for vaginal cuff closure
Number of subjects: 70
Study 27426680 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach and Vaginal route
Number of subjects: 70
Study 25137036 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-resveratrol (500 mg) three times per day for 90 days
Number of subjects: 24
Study 22704095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral advancement during laparoscopic extravesical ureteral reimplantation
Number of subjects: 30
Study 22704095 — intervention group
Group type: COMPARATOR
Intervention: Non-advancement during laparoscopic extravesical ureteral reimplantation
Number of subjects: 30
Study 20979893 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant posterior minimally invasive surgery system (n = 30)
Number of subjects: 61
Study 20979893 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery (n = 31)
Number of subjects: 61
Study 18570574 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin-metronidazole
Number of subjects: 244
Study 18570574 — intervention group
Group type: COMPARATOR
Intervention: piperacillin-tazobactam
Number of subjects: 244
Study 18570574 — intervention group
Group type: EXPERIMENTAL
Intervention: appendicitis patients
Number of subjects: 244
Study 18570574 — intervention group
Group type: COMPARATOR
Intervention: other infections
Number of subjects: 244
Study 15850121 — intervention group
Group type: COMPARATOR
Intervention: Pen tablet system for evaluation of hand motion control function; subjects instructed to tap 50 times with each hand.
Number of subjects: 13
Study 12418296 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days
Number of subjects: 203
Study 12418296 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin during 5 days, by infusion
Number of subjects: 203
Study 10321676 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS simulation program
Number of subjects: 45
Study 10321676 — intervention group
Group type: COMPARATOR
Intervention: Textbook review
Number of subjects: 45
Study 8166101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC light-activated glass polyalkenoate cement (GC Industrial Co., Tokyo, Japan)
Number of subjects: 0
Study 8166101 — intervention group
Group type: COMPARATOR
Intervention: System I+ composite bonding resin (Ormco Corp., Glendora, Calif.)
Number of subjects: 0
Study 3254762 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine
Number of subjects: 21
Study 3254762 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyl-L-tyrosine
Number of subjects: 21
Study 3254762 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine and Glycyl-L-tyrosine
Number of subjects: 21
Study 29576126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused B-mode and elastography videos with 0.25 ml volumes
Number of subjects: 22
Study 29576126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused B-mode and elastography videos
Number of subjects: 22
Study 29576126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused elastography
Number of subjects: 22
Study 29576126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml volumes
Number of subjects: 22
Study 29576126 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml volumes
Number of subjects: 22